US-based drugmaker Moderna on Monday said its Covid-19 vaccine retains neutralising activity against emerging variants first identified in the UK and South Africa.

Vaccination with the Moderna Covid-19 Vaccine produced neutralising titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and South Africa, respectively, the company said on the basis of a study.